Early diagnosis of tuberculosis (TB) is crucial for the treatment to be effective, said the Ministry of Health and Family ...

In the modern workplace, many professions demand that employees spend long hours sitting. If workers in these occupations do not actively ...

Help Register Login Login Hi, %{firstName}% Hi, %{firstName}% Games Car rental A new kind of prescription drug is dramatically changing the treatment of Type 2 diabetes and obesity, yet a new AARP ...

Obesity is a growing health concern worldwide, affecting millions of people. It not only impacts physical appearance but also increases the risk of several chronic diseases, including diabetes, heart ...

Nearly 137 million American adults are eligible to use these costly drugs to treat diabetes and obesity, or for secondary prevention of cardiovascular disease. That’s more than half of our adult ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...

(Relevance: India is suffering from the double burden of malnutrition and rising obesity. Recently, the Prime Minister also emphasized reducing oil consumption by 10%. He has nominated celebrities to ...

Some dogs, like Labrador retrievers, are prone to obesity. Scientists have investigated the genetics of British Labrador retrievers and found several obesity-linked genes that were then also ...

Shares in Novo Nordisk fell on Monday on a second set of worse than expected trial results for the latest obesity drug from the manufacturer of blockbuster treatments Ozempic and Wegovy.

A new study claims there are two kinds of obesity – one of which puts you at risk of major health problems. Find out which camp you’re in ...

LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...

Ms Mishlawi said the current medicines were “only the beginning” because there are so many new obesity drugs being developed. Some US health insurers and many European healthcare systems are ...